Avadel pharmaceuticals announces publication of restore data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly lumryz™ dosing (sodium oxybate) extended-release oral suspension (ciii)

– survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of lumryz over twice-nightly oxybate regimens –

AVDL Ratings Summary

AVDL Quant Ranking